$ATYR News

aTyr Pharma Q1 EPS $(0.11) Beats $(0.14) Estimate

aTyr Pharma, Inc. (ATYR) Discusses FDA Feedback and Next Steps for Efzofitimod in Pulmonary Sarcoidosis After Phase III Results - Slideshow

aTyr Pharma, Inc. (ATYR) Discusses FDA Feedback and Next Steps for Efzofitimod in Pulmonary Sarcoidosis After Phase III Results Transcript

aTyr Pharma Revamps Efzofitimod Path With New Phase III Sarcoidosis Trial

aTyr Pharma Provides Regulatory and Clinical Update for Efzofitimod in Pulmonary Sarcoidosis Following FDA Type C Meeting

Interstitial Lung Disease Market to Witness Accelerated Growth at a CAGR of 8.7% During the Forecast Period (2026–2036) Due to the Launch of Emerging Therapies | DelveInsight

aTyr Pharma Spotlights Efzofitimod Phase 3 Learnings, Eyes Mid-April FDA Type C Meeting

Atyr Pharma: Q4 Earnings Snapshot

aTyr Pharma Announces Fourth Quarter and Full Year 2025 Results and Provides Corporate Update

aTyr Pharma Q4 EPS $(0.14) Beats $(0.16) Estimate

aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

aTyr Pharma to Present at the Leerink Partners Global Healthcare Conference

aTyr Pharma Announces Scheduling of FDA Type C Meeting to Discuss Efzofitimod Program in Pulmonary Sarcoidosis

aTyr Pharma Announces Mid-April 2026 FDA Meeting To Discuss Path Forward For Efzofitimod In Pulmonary Sarcoidosis After Phase 3 Study

aTyr Pharma Announces Mid-April 2026 FDA Meeting To Discuss Path Forward For Efzofitimod In Pulmonary Sarcoidosis After Phase 3 Study

Is aTyr Pharma (NASDAQ:ATYR) In A Good Position To Deliver On Growth Plans?

aTyr Pharma to Present at Piper Sandler 37th Annual Healthcare Conference

RBC Capital Maintains Sector Perform on aTyr Pharma, Lowers Price Target to $1

Atyr Pharma: Q3 Earnings Snapshot

aTyr Pharma Announces Third Quarter 2025 Results and Provides Corporate Update